Duvakitug Phase 2b Results Highlight Potential in IBD Treatment
Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., have announced promising results from the RELIEVE UCCD phase 2b study, which met its primary endpoints in patients…
FDA Grants Breakthrough Status to Trodelvy for 2nd-Line ES-SCLC Treatment
Gilead Sciences, Inc announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for adult patients with extensive-stage small cell lung cancer…
Gilead & Terray Partner on Multi-Target Small Molecule Therapies
Gilead Sciences, Inc and Terray Therapeutics, Inc. have entered into a strategic collaboration aimed at discovering and developing novel small molecule therapies across multiple therapeutic targets. This partnership leverages Terray’s…
Merck Updates KeyVibe & KEYFORM Trials for Cancer Combos
Merck known as MSD outside of the United States and Canada, has announced the discontinuation of clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. Vibostolimab…
ViiV: CHMP Backs Long-Acting HIV Treatment for Adolescents in Europe
GSK plc has announced that ViiV Healthcare, the global HIV-focused company majority owned by GSK with Pfizer and Shionogi as shareholders, received a positive opinion from the Committee for Medicinal…
Grifols Named Top Biotech Company in Dow Jones Sustainability Indices
Grifols, a global healthcare leader and prominent manufacturer of plasma-derived medicines, has achieved the distinction of being ranked the number one biotechnology company in the S&P Dow Jones Sustainability Indices…
ORCHESTRA Study Insights Guide Next Steps in UCB s Parkinson’s Research Program
UCB has announced results from the ORCHESTRA proof-of-concept study evaluating minzasolmin, an investigational oral small molecule developed in collaboration with Novartis to inhibit alpha-synuclein misfolding in early-stage Parkinson’s disease. Unfortunately,…
Jazz Pharmaceuticals Unveils CEO Succession Plan
Jazz Pharmaceuticals plc has announced a pivotal leadership transition, as Bruce Cozadd, the company’s Co-Founder, Chairperson, and Chief Executive Officer (CEO), plans to retire from his role upon the appointment…
Enhancing Health and Care Worker Training to Foster Resilient Health Systems
We, the member countries of the Group of Friends of the WHO Academy, reaffirm our steadfast commitment to supporting the WHO Academy as a vital mechanism for enhancing the skills…
Lupin Digital Health Collaborates with Medicover Hospitals to Enhance Post-Discharge Cardiac Care
Lupin Digital Health, a wholly owned subsidiary of the global pharmaceutical leader Lupin Limited, has announced a strategic collaboration with Medicover Hospitals to enhance cardiac care for patients in India.…
Lupin Acquires 3 Diabetes Trademarks from Boehringer Ingelheim
Lupin Limited, a leading global pharmaceutical company, has announced the acquisition of three key anti-diabetes trademarks—GIBTULIO®, GIBTULIO MET®, and AJADUO®—from Boehringer Ingelheim International GmbH. This strategic move is aimed at…
Neurocrine Announces FDA Approval of CRENESSITY for Congenital Adrenal Hyperplasia
Neurocrine Biosciences,has announced that the U.S. Food and Drug Administration (FDA) has approved CRENESSITY™ (crinecerfont) capsules and oral solution for use as an adjunctive treatment to glucocorticoid replacement in adults…